

## BOTOX<sup>®</sup> in Canada

### WHAT IS BOTOX<sup>®</sup>?

BOTOX<sup>®</sup> (botulinum toxin type A) is a purified protein derived from the bacterium *Clostridium botulinum* and decreases muscle activity by blocking overactive nerve impulses that trigger excessive muscle contractions or glandular activities.

BOTOX<sup>®</sup> is a simple, minimally invasive treatment that can deliver effective results to a wide range of patients, ranging from very compromised patients to healthy individuals who want to feel their best.

### WHAT IS BOTOX<sup>®</sup> USED FOR?

BOTOX<sup>®</sup> was first approved by Health Canada in 1990 for the treatment of strabismus (crossed eyes), blepharospasm (uncontrollable blinking), and VII nerve disorder. Other approvals for the medical uses of BOTOX<sup>®</sup> soon followed and included indications for:

- Focal spasticity (muscle tightness that affects a small part of the body after a stroke),
- Cervical dystonia (muscle contractions in the neck),
- Pediatric cerebral palsy dynamic equinus foot deformity, and
- Axillary hyperhidrosis (excessive underarm sweating).<sup>1</sup>

In 2001, the same product, marketed under the name BOTOX Cosmetic<sup>®</sup>, was approved for the treatment of:

- Glabellar lines (vertical “frown lines” between the eyebrows),
- Upper facial rhytides (forehead wrinkles), and
- Lateral canthus (crow’s feet).<sup>2</sup>

Today, BOTOX<sup>®</sup> benefits **21 different patient populations** across approximately **80 countries** over the past 20 years.<sup>3</sup> The safety and efficacy of the product has been well-established in more than **11,000 patients** in more than **50 Allergan-sponsored, randomized, placebo-controlled clinical trials**. With **100 years of study** and more than **2,100 articles** in peer-reviewed, clinical publications, BOTOX<sup>®</sup> is one of the most widely researched medicines in the world.<sup>4</sup> With more than 26 million vials of BOTOX<sup>®</sup> and BOTOX<sup>®</sup> Cosmetic distributed over the past 20 years and more than 29 million treatment sessions performed around the world, serious adverse events have been reported rarely with this product.<sup>5</sup>

- 30 -

**For more information, please contact:**

Jacqueline Zonneville  
NATIONAL Public Relations  
[jzonneville@national.ca](mailto:jzonneville@national.ca)  
416-848-1398

**REFERENCES:**

- 
- 1 BOTOX<sup>®</sup> Product Monograph
  - 2 BOTOX Cosmetic<sup>®</sup> Product Monograph
  - 3 Allergan data on file
  - 4 Allergan data on file; Global Literature and Information Services.
  - 5 Allergan data on file; Global Regulatory Affairs.